NASDAQ:BCDAW

BioCardia (BCDAW) Stock Price, News & Analysis

$0.02
0.00 (0.00%)
(As of 04/23/2024 ET)
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.04
52-Week Range
$0.01
$1.38
Volume
750 shs
Average Volume
12,186 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BCDAW stock logo

About BioCardia Stock (NASDAQ:BCDAW)

BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

BCDAW Stock Price History

BCDAW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive BCDAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BCDAW
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$477,000.00

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Peter A. Altman Ph.D. (Age 57)
    CEO, President & Director
    Comp: $515.51k
  • Mr. David McClung (Age 61)
    Chief Financial Officer
    Comp: $370.86k
  • Mr. Edward M. Gillis (Age 62)
    Senior Vice President of Devices
    Comp: $263.1k

BCDAW Stock Analysis - Frequently Asked Questions

How have BCDAW shares performed in 2024?

BioCardia's stock was trading at $0.0125 at the beginning of 2024. Since then, BCDAW shares have increased by 75.2% and is now trading at $0.0219.
View the best growth stocks for 2024 here
.

How do I buy shares of BioCardia?

Shares of BCDAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCDAW) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners